HIGHBuilt-inPipeline
product candidates
“10-K Item 1A: 'We are substantially dependent on the success of our product candidates.'”
OCGN · Concentration risk · 10-K extracted
Ocugen (OCGN) concentration risks
Updated
The most significant concentration Ocugen discloses is product candidates, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Ocugen’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
CanSinoBIO
“10-K Item 1: 'CanSinoBIO has state-of-the-art facilities and proven expertise in the gene therapy field, which is critical to advancing our gene therapy product candidates'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Ocugen's business is built around the success of its product candidates as a whole: the company states it is substantially dependent on their success, a high and structural exposure common to clinical-stage biotechnology companies that have not yet generated meaningful commercial revenue. This is not a customer or geographic risk but a reflection of the binary nature of drug development itself — value depends on clinical, regulatory, and commercial outcomes across the pipeline rather than on any single revenue stream. Layered on top of that structural risk is a moderate manufacturing dependency: Ocugen relies on CanSinoBIO, whose facilities and expertise it describes as critical to advancing its gene therapy candidates. This is a narrower, idiosyncratic counterparty risk — a disruption at CanSinoBIO could delay specific programs even if the underlying science remains sound. Together, the two exposures compound in a single direction: pipeline-wide clinical risk sets the ceiling on the company's prospects, while the CanSinoBIO dependency is one of the concrete operational risks that could delay realization of that value, making execution risk, not diversification, the central issue for the story.
For the engine’s reasoning on OCGN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| OCGN● | Ocugen, Inc. | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.